Author/Authors :
Ghafourian Boroujerdnia، Mehri نويسنده Immunology Department, Medical College, Ahvaz Jundishapur University of Medical Science, Ahvaz, IR Iran Ghafourian Boroujerdnia, Mehri , Assarehzadegan، Mohammad Ali نويسنده Department of Immunology, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IR Iran , , Zandian، Khodamorad نويسنده Hemoglobinopathy and Thalassemia Research Center, Shafa Hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IR Iran ,
Abstract :
Background: Although it is life-saving, blood transfusion therapy has resulted in risk for transfusion-transmitted infections (TTIs) in the majority of sickle cell anemia being patients.
Objectives: The current study aimed to determine the prevalence of HBV, HCV and different genotypes of HCV among sickle cell anemia (SCA) patients in Ahvaz city, South-western Iran.
Materials and Methods: A cross-sectional study was conducted on 56 SCA patients who referred to the Hemoglobinopathy and Thalassemia research centre during January 2009 to February 2010. Patients` sera were tested for HBsAg and anti-HCV using ELISA and confirmed by PCR (HBV) and RT-PCR (HCV). HCV genotypes were determined with HCV genotype specific primers using HCV genotyping kit.
Results: The overall prevalence rate of HBsAg and anti-HCV were 1.8% (95% CI: 0-5.26) and 12.5% (95% CI: 3.8 - 21.1), respectively. Five of the anti-HCV patients (71.4%) were also HCV RNA positive. The predominant HCV genotype in the patients was 1a (60%), though genotype 1b was found in 40% of the subjects.
Conclusions: It seems that stringent donor selection procedures reduce HCV infection in multi-transfused patients, but there is still serious risk for these patients.
